文献速递肾小球疾病慢性肾脏病

Sparsentan在PROTECT研究中的IgA肾病患者基线特征

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
PubMed 文献 · Kidney Int Rep · 2023-03-04

PROTECT是一项多中心、国际、随机、双盲、平行组、活性对照的3期试验,评估sparsentan对比厄贝沙坦在经活检证实且蛋白尿≥1.0 g/d的成人IgA肾病患者中的疗效与安全性。共404例随机并接受研究药物的患者纳入主要分析人群,中位年龄46岁,基线中位尿蛋白排泄1.8 g/d,35%患者处于CKD 3B期。

要点

  • PROTECT研究纳入404例经活检证实、蛋白尿≥1.0 g/d的成人IgA肾病患者。
  • 基线中位尿蛋白排泄为1.8 g/d,35%患者处于CKD 3B期。
  • 63.4%患者在转换研究药物前接受最大标签剂量ACEi或ARB治疗。

核心结论

  • PROTECT研究的患者入组涵盖不同种族背景和CKD分期,将有助于重要地表征sparsentan在蛋白尿型高肾衰竭风险IgA肾病患者中的治疗效果。

研究设计与样本

  • PROTECT试验(NCT03762850)是多中心、国际、随机、双盲、平行组、活性对照研究,评估sparsentan对比活性对照厄贝沙坦在经活检证实IgA肾病且蛋白尿≥1.0 g/d的成人中的疗效与安全性,这些患者尽管已接受ACEi和/或ARB最大化治疗至少12周。
  • 主要分析人群包括404例随机并接受研究药物的患者,中位年龄46岁;患者来自欧洲(53%)、亚太(27%)和北美(20%)。

主要发现

  • 基线中位尿蛋白排泄为1.8 g/d。
  • eGFR范围广泛,最大比例患者(35%)处于CKD 3B期。
  • 转换研究药物前,平均收缩压/舒张压为129/82 mm Hg,大多数患者(63.4%)接受最大标签剂量ACEi或ARB。
  • 亚洲地区对比非亚洲地区患者:女性比例更高、血压更低、高血压病史和基线降压治疗比例更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). METHODS: The PROTECT trial (NCT03762850) is a multicenter, international, randomized, double-blind, parallel-group, active-controlled study. The efficacy and safety of sparsentan versus the active control irbesartan is being evaluated in adults with biopsy-proven IgAN and proteinuria ≥1.0 g/d despite maximized treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB) for at least 12 weeks. Blinded and aggregated baseline characteristics are reported descriptively and compared to contemporary phase 3 trials with patients with IgAN. RESULTS: The primary analysis population includes 404 patients who were randomized and received study drug (median age, 46 years). Enrolled patients were from Europe (53%), Asia Pacific (27%), and North America (20%). Baseline median urinary protein excretion was 1.8 g/d. The range of estimated glomerular filtration rate (eGFR) was broad with the largest proportion of patients (35%) in chronic kidney disease (CKD) stage 3B. Before transitioning to study medication, mean systolic/diastolic blood pressure was 129/82 mm Hg, with the majority of patients (63.4%) receiving the maximum labeled ACEi or ARB dose. Patients in Asian versus non-Asian regions included a higher percentage of females, had lower blood pressures, and included lower proportions of patients with a history of hypertension and baseline antihypertensive treatment. CONCLUSIONS: Patient enrollment in PROTECT, with differing racial backgrounds and across CKD stages, will allow for important characterization of the treatment effect of sparsentan in patients with IgAN with proteinuria at high risk of kidney failure.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Barratt J, Rovin B, Wong MG, et al. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney Int Rep. 2023. PMID: 37180506. doi:10.1016/j.ekir.2023.02.1086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。